Oral · GLP-1 agonist
IBI3042
3 trials in this molecule. Source: ClinicalTrials.gov, as of November 5, 2026.
Trials
3
Ongoing
3
Recruiting
1
Completed
0
Sites
3
Countries
2
Endpoints
81
Composite endpoints
0
Distinct sites and countries across this molecule's trials. A site running several of its trials counts once, matching the map.
Where the program stands
Trials by phase
Phase 1
3
Trials by status
Not yet recruiting
2
Recruiting
1
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Safety / tolerability / PK
71
Weight & body composition
9
Glycemic / diabetes
1
Top 20 metrics across this asset's endpoints
Programs for this asset
Every trial for this molecule, with the same search, filters, and sort as the Trials tab.
⌘K
3 of 3
| Asset / Population | Eligibility highlight | Evidence | ||||||
|---|---|---|---|---|---|---|---|---|
| NCT07842393A Study of IBI3042 in Healthy Adult Participants | IBI3042 Healthy volunteers | BMI 20-32 | Ph 1 | Not yet recruiting | 1 | Feb 2027 | - | |
| NCT07802899An Exploratory Study of Single-Dose and Multiple-Doses IBI3042 in Healthy, Overweight, or Obese Participants | IBI3042 Obesity / overweight | BMI 20-28 | Ph 1 | Not yet recruiting | 1 | Mar 2027 | - | |
| NCT07793019IBI3042 Study in Healthy Participants and Overweight or Obese Participants | IBI3042, Orforglipron Healthy volunteers, Obesity / overweight | BMI 20-30 | Ph 1 | Recruiting | 1 | Sep 2027 | - |
Showing 1-3 of 3 trials